Table 1.
Characteristics | First ascertained SARS-CoV-2 infections | Admission type | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Total | Positive SARS-CoV-2 test result only | SARS-CoV-2 associated hospital admission | Nosocomial | Type C (incidental) | Paediatric inflammatory multisystem syndrome | Type A1 (caused by SARS-CoV-2 ) | Type A2 (suspected caused by SARS-CoV-2) | Type B1 (causal pathway) | Type B2 (causal pathway) | ||
Total No | 3 226 535 | 3 197 305 | 29 230 | 380 | 7855 | 1790 | 9875 | 5330 | 2005 | 2000 | |
Sex | |||||||||||
Female | 1 618 030 (50.1) | 1 604 175 (50.2) | 13 855 (47.4) | 245 (64.5) | 4000 (50.9) | 715 (39.9) | 4640 (47.0) | 2465 (46.2) | 865 (43.1) | 920 (46.0) | |
Male | 1 608 505 (49.9) | 1 593 130 (49.8) | 15 375 (52.6) | 135 (35.5) | 3855 (49.1) | 1075 (60.1) | 5235 (53.0) | 2860 (53.7) | 1135 (56.6) | 1080 (54.0) | |
Age | |||||||||||
Median (interquartile range) age (years) | 11.4 (8.1-14.4) | 11.5 (8.1-14.4) | 5.5 (0.6-12.9) | 7.4 (0.7-16.0) | 10.6 (3.5-15.0) | 7.6 (3.8-11.3) | 1.3 (0.2-10.1) | 4.1 (1.1-11.3) | 1.2 (0.2-10.4) | 9.5 (4.6-14.1) | |
Age group (years): | |||||||||||
<1 | 41 360 (1.2) | 32 940 (1.0) | 8415 (28.7) | 120 (31.5) | 1190 (15.2) | 90 (5.1) | 4590 (46.6) | 1265 (23.7) | 960 (47.8) | 210 (10.4) | |
1-4 | 273 785 (8.5) | 268 070 (8.4) | 5720 (19.6) | 65 (17.1) | 1150 (14.6) | 505 (28.2) | 1770 (17.9) | 1610 (30.2) | 290 (14.5) | 330 (16.5) | |
5-11 | 1 461 130 (45.3) | 1 454 290 (45.5) | 6840 (23.4) | 20 (5.3) | 2100 (26.7) | 840 (46.9) | 1545 (15.6) | 1265 (23.7) | 350 (17.5) | 715 (35.8) | |
12-15 | 1 044 335 (32.4) | 1 039 080 (32.5) | 5255 (18.0) | 85 (22.4) | 2125 (27.1) | 305 (17.0) | 1225 (12.4) | 765 (14.4) | 255 (12.7) | 495 (24.8) | |
16-17 | 405 925 (12.6) | 402 925 (12.6) | 3000 (10.3) | 90 (23.7) | 1290 (16.4) | 50 (2.8) | 745 (7.5) | 425 (8.0) | 150 (7.5) | 250 (12.5) | |
Ethnic group | |||||||||||
Asian or Asian British | 274 870 (8.5) | 270 510 (8.5) | 4360 (15.0) | 40 (10.5) | 1000 (12.8) | 355 (19.9) | 1570 (16.0) | 750 (14.1) | 290 (14.5) | 345 (17.2) | |
Black or black British | 87 725 (2.7) | 85 865 (2.7) | 1860 (6.4) | 25 (6.6) | 435 (5.5) | 235 (13.1) | 565 (5.7) | 245 (4.6) | 135 (6.7) | 220 (11.0) | |
Chinese | 16 350 (0.5) | 16 250 (0.5) | 100 (0.3) | 0 (0.0) | 25 (0.3) | 15 (0.8) | 40 (0.4) | 15 (0.3) | <10 (<0.5) | <10 (<0.5) | |
Mixed | 127 880 (4.0) | 126 325 (4.0) | 1555 (5.3) | 25 (6.6) | 380 (4.8) | 130 (7.3) | 555 (5.6) | 260 (4.9) | 110 (5.5) | 90 (4.5) | |
Other | 59 990 (1.9) | 59 050 (1.8) | 940 (3.2) | <10 (<2.6) | 225 (2.9) | 65 (3.6) | 360 (3.6) | 160 (3.0) | 70 (3.5) | 55 (2.8) | |
Unknown | 36 915 (1.1) | 36 685 (1.1) | 235 (0.8) | <10 (<2.6) | 55 (0.7) | 15 (0.8) | 85 (0.9) | 50 (0.9) | 15 (0.7) | 15 (0.8) | |
White | 2 622 805 (81.3) | 2 602 620 (81.4) | 20 180 (69.0) | 275 (72.4) | 5735 (73.0) | 975 (54.5) | 6700 (67.8) | 3850 (72.2) | 1380 (68.8) | 1265 (63.2) | |
Index of multiple deprivation fifth | |||||||||||
1st (most deprived) | 625 285 (19.3) | 616 440 (19.3) | 8845 (30.3) | 95 (25.0) | 2515 (32.0) | 480 (26.8) | 2945 (29.8) | 1525 (28.7) | 635 (31.6) | 645 (32.1) | |
2nd | 592 080 (18.4) | 585 575 (18.3) | 6505 (22.3) | 100 (26.3) | 1685 (21.5) | 395 (22.1) | 2195 (22.2) | 1205 (22.6) | 475 (23.7) | 455 (22.8) | |
3rd | 622 550 (19.3) | 617 370 (19.3) | 5180 (17.7) | 75 (19.7) | 1315 (16.7) | 335 (18.7) | 1820 (18.4) | 940 (17.6) | 365 (18.2) | 335 (16.8) | |
4th | 654 815 (20.3) | 650 160 (20.3) | 4655 (15.9) | 60 (15.8) | 1230 (15.7) | 305 (17.0) | 1595 (16.2) | 880 (16.5) | 280 (14.0) | 310 (15.5) | |
5th (least deprived) | 731 805 (22.7) | 727 760 (22.8) | 4045 (13.8) | 50 (13.2) | 1110 (14.1) | 275 (15.4) | 1320 (13.4) | 780 (14.6) | 250 (12.5) | 255 (12.8) | |
Underlying health conditions | |||||||||||
Health condition linked to clinical vulnerability | 580 195 (18.0) | 569 110 (17.8) | 11 085 (37.9) | 210 (55.3) | 2550 (32.5) | 515 (28.8) | 3190 (32.3) | 1730 (32.5) | 1140 (56.9) | 1745 (87.2) | |
Medical and developmental condition | 939 965 (29.1) | 923 690 (28.9) | 16 275 (55.7) | 280 (73.7) | 3880 (49.4) | 1020 (57.0) | 4815 (48.8) | 2795 (52.4) | 1500 (74.8) | 1990 (99.5) | |
Hospital admission features | |||||||||||
Covid-19 positivity in window* | - | - | 23 750 (81.3) | 380 (100.0) | 7005 (89.2) | 130 (7.3) | 8135 (82.4) | 4615 (86.6) | 1695 (84.5) | 1795 (89.8) | |
Length of stay | - | - | 2 (1 4) | 93 (42 162) | 2 (1 4) | 6 (4 8) | 2 (1 3) | 2 (1 2) | 3 (2 6) | 2 (1 3) | |
Still in hospital | - | - | 160 (0.5) | 95 (25.0) | 40 (0.5) | 0 (0.0) | <10 (<0.1) | <10 (<0.2) | 15 (0.7) | <10 (<0.5) | |
ICU or HDU care | - | - | 1710 (5.9) | 105 (27.6) | 255 (3.2) | 535 (29.9) | 315 (3.2) | 95 (1.8) | 320 (16.0) | 85 (4.2) | |
Day patient | - | - | 1805 (6.2) | 0 (0.0) | 815 (10.4) | 85 (4.7) | 70 (0.7) | 95 (1.8) | 75 (3.7) | 665 (33.2) | |
Vaccination status 14 days before infection | |||||||||||
Unvaccinated | 2 878 355 (89.2) | 2 850 515 (89.1) | 27 840 (95.2) | 340 (89.5) | 7290 (92.8) | 1760 (98.3) | 9605 (97.2) | 5115 (96.0) | 1925 (96.0) | 1805 (90.2) | |
First dose | 297 030 (9.2) | 296 010 (9.3) | 1020 (3.5) | 30 (7.9) | 445 (5.7) | 25 (1.4) | 180 (1.8) | 160 (3.0) | 55 (2.7) | 125 (6.2) | |
Second dose | 48 875 (1.5) | 48 560 (1.5) | 315 (1.1) | <10 (<2.6) | 110 (1.4) | <10 (<0.6) | 65 (0.7) | 45 (0.8) | 25 (1.2) | 60 (3.0) | |
Booster dose | 2275 (0.1) | 2220 (0.1) | 55 (0.2) | <10 (<2.6) | 10 (0.1) | 0 (0.0) | 25 (0.3) | <10 (<0.2) | <10 (<0.5) | <10 (<0.5) | |
Variant period | |||||||||||
Original | 127 205 (3.8) | 124 770 (3.8) | 2450 (8.3) | 35 (9.2) | 730 (9.4) | 230 (12.8) | 690 (6.9) | 430 (8.1) | 155 (7.8) | 175 (8.7) | |
Original-alpha | 101 885 (3.2) | 100 435 (3.1) | 1450 (5.0) | 35 (9.2) | 410 (5.2) | 105 (5.9) | 445 (4.5) | 240 (4.5) | 120 (6.0) | 95 (4.7) | |
Alpha | 158 960 (4.9) | 155 660 (4.9) | 3300 (11.3) | 60 (15.8) | 895 (11.4) | 425 (23.7) | 945 (9.6) | 575 (10.8) | 185 (9.2) | 210 (10.4) | |
Alpha-delta | 15 525 (0.5) | 15 260 (0.5) | 260 (0.9) | <10 (<2.6) | 65 (0.8) | 35 (2.0) | 75 (0.8) | 50 (0.9) | 25 (1.2) | 15 (0.8) | |
Delta | 1 612 630 (50.0) | 1 601 445 (50.1) | 11 185 (38.3) | 95 (25.0) | 2945 (37.5) | 725 (40.5) | 3995 (40.5) | 1915 (35.9) | 820 (40.9) | 695 (34.8) | |
Delta-omicron | 195 475 (6.1) | 194 125 (6.1) | 1345 (4.6) | 25 (6.6) | 340 (4.3) | 70 (3.9) | 455 (4.6) | 240 (4.5) | 100 (5.0) | 115 (5.8) | |
Omicron | 1 014 855 (31.5) | 1 005 610 (31.5) | 9240 (31.6) | 125 (32.9) | 2470 (31.4) | 200 (11.2) | 3270 (33.1) | 1880 (35.3) | 600 (29.9) | 695 (34.8) | |
Mortality | |||||||||||
Death | 295 (0.0) | 130 (0.0) | 165 (0.6) | <10 (<2.6) | 30 (0.4) | <10 (<0.6) | 60 (0.6) | 15 (0.3) | 30 (1.5) | 20 (1.0) | |
Hospital death: | 70 (0.0) | <10 (0.0*) | 65 (0.2) | <10 (<2.6) | 10 (0.1) | 0 (0.0) | 30 (0.3) | <10 (<0.2) | 15 (0.7) | <10 (<0.5) | |
Covid-19 or PIMS-TS related | 70 (0.0) | 20 (0.0) | 55 (0.2) | <10 (<2.6) | <10 (<0.1) | 0 (0.0) | 35 (0.4) | <10 (<0.2) | <10 (<0.5) | <10 (<0.5) | |
Covid-19 or PIMS-TS underlying | 55 (0.0) | 15 (0.0) | 40 (0.1) | 0 (0.0) | <10 (<0.1) | 0 (0.0) | 30 (0.3) | <10 (<0.2) | <10 (<0.5) | 0 (0.0) | |
Covid-19 or PIMS-TS related hospital death | 40 (0.0) | 0 (0.0) | 40 (0.1) | <10 (<2.6) | <10 (<0.1) | 0 (0.0) | 25 (0.3) | <10 (<0.2) | <10 (<0.5) | <10 (<0.5) | |
Covid-19 or PIMS-TS underlying hospital death | 30 (0.0) | 0 (0.0) | 30 (0.1) | 0 (0.0) | <10 (<0.1) | 0 (0.0) | 25 (0.3) | <10 (<0.2) | <10 (<0.5) | 0 (0.0) |
PIMS-TS=paediatric Inflammatory multisystem syndrome with a temporal association with SARS-CoV-2.
Counted only when test occurred 14 days before date of admission up to discharge—this window defines an admission as SARS-CoV-2-related, and it could be (but equally may not be the sole) reason for the inclusion of these participants in the applicable group.